Literature DB >> 3887629

Assessment of alanine, urea, and glucose interrelationships in normal subjects and in patients with sepsis with stable isotopic tracers.

J H Shaw, S Klein, R R Wolfe.   

Abstract

The kinetic interactions among glucose, alanine, and urea metabolism were studied in both normal volunteers and in patients with sepsis by means of a primed, constant infusion of stable isotopes. In the normal volunteers, infusion of glucose at 4 mg/kg/min suppressed total glucose production, the rate of gluconeogenesis from alanine, and the production of urea, despite an increase in the rate of release and uptake of alanine. When the glucose infusion rate was increased to 8 mg/kg/min, the production of urea decreased further, even though gluconeogenesis from alanine was already suppressed by the first infusion. This additional N-sparing effect was explainable by an increase in glucose oxidation. In the patients with sepsis the basal rates of production of glucose and urea were elevated significantly. Glucose infusion (4 mg/kg/min) decreased hepatic glycogenolysis but not gluconeogenesis from alanine or urea production. At the glucose infusion rate of 8 mg/kg/min, glucose oxidation increased in the patients and urea production decreased. Thus in patients with sepsis a higher rate of glucose infusion is necessary to achieve nitrogen-sparing effects than is necessary in controls because of a lack of suppressibility of gluconeogenesis. Because of continued glucose production during glucose infusion, hyperglycemia commonly develops during glucose infusion in sepsis. However, this effect does not necessarily indicate a complete inability of the patient with sepsis to benefit nutritionally from infused glucose, as we observed no decrement in the ability to oxidize infused glucose.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887629

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

Review 1.  Enteral nutrition and acute pancreatitis.

Authors:  Q P Chen
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Glucose, fatty acid, and urea kinetics in patients with severe pancreatitis. The response to substrate infusion and total parenteral nutrition.

Authors:  J H Shaw; R R Wolfe
Journal:  Ann Surg       Date:  1986-12       Impact factor: 12.969

3.  Nutrition in respiratory failure.

Authors:  G Iapichino
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

4.  Whole body protein kinetics in severely septic patients. The response to glucose infusion and total parenteral nutrition.

Authors:  J H Shaw; M Wildbore; R R Wolfe
Journal:  Ann Surg       Date:  1987-03       Impact factor: 12.969

Review 5.  Nutritional support in the management of critically ill patients in surgical intensive care.

Authors:  S J Streat; G L Hill
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

6.  Insulin responses to glucose and isoproterenol decrease with age.

Authors:  James M Watters
Journal:  Can J Surg       Date:  2005-04       Impact factor: 2.089

7.  Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity.

Authors:  V Hack; O Stütz; R Kinscherf; M Schykowski; M Kellerer; E Holm; W Dröge
Journal:  J Mol Med (Berl)       Date:  1996-06       Impact factor: 4.599

8.  The effect of tumor bulk on the metabolic response to cancer.

Authors:  J B Koea; J H Shaw
Journal:  Ann Surg       Date:  1992-03       Impact factor: 12.969

9.  Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine.

Authors:  R Kinscherf; V Hack; T Fischbach; B Friedmann; C Weiss; L Edler; P Bärtsch; W Dröge
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

10.  Energy and protein metabolism in sarcoma patients.

Authors:  J H Shaw; D M Humberstone; R R Wolfe
Journal:  Ann Surg       Date:  1988-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.